Acorda Therapeutics (ACORQ) 10-Q2022 Q1 Quarterly report

Filed: 13 May 22, 9:25am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: appeal, April, Arzneimittel, binding, Brazil, budget, cap, confidentiality, convenience, dalmfapridine, departure, difficulty, disclaim, dismissed, dryer, electronic, exceed, exit, formality, hearing, inadmissible, indemnity, individual, installation, intent, inventive, Latin, lessen, Mexico, mobility, newly, novelty, nurse, Opposition, overstocking, ownership, paragraph, preliminary, profitability, proper, qualification, recalculation, repatriation, seek, seeking, shipping, short, sooner, sought, spray, STADA, step, suspended, tablet, Technical, Troubled, upheld, usage, Vintage, virtual, warehouse

Removed: ACOR, acute, affiliated, AOCI, applied, assessing, assume, asthma, Ave, awarded, began, blind, carryback, categorized, Certificate, children, chronic, clinical, comparable, comparing, comprehensive, controlled, COPD, cough, decision, directly, discolored, double, Eastern, endpoint, equally, escalation, establish, Everett, expiratory, exploring, extension, factor, forward, freight, grant, hired, holding, idle, incentive, Incorporation, infection, investment, Kingdom, lack, Lancet, left, longest, maker, meaningful, measure, medicine, migraine, mild, moderate, modify, monoamine, move, Nasdaq, nausea, Neurology, nonselective, North, notified, observational, obstructive, occupancy, onset, open, operation, operational, organization, owner, oxidase, packaging, paper, peak, pertain, pertaining, Phase, phenelzine, pivotal, placebo, posted, projection, proportionate, publicly, published, randomized, ratification, Rating, reconcile, recover, recovery, relate, repayment, reserved, respiratory, restated, retroactively, River, safe, save, scale, score, seasonally, Select, showed, showing, sputum, stability, statistically, studied, study, suitability, symbol, testing, tolerability, tract, transition, tranylcypromine, understanding, Unified, upper, validated, viewed, week, Withdrawal

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ACORQ transcripts

ACORQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Acorda Therapeutics, Inc. (the “Company”) for the fiscal quarter ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ron Cohen, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Ron Cohen

Ron Cohen

Chief Executive Officer

(Principal Executive Officer)

May 13, 2022

[A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Acorda Therapeutics, Inc. and will be retained by Acorda Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.]

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.